(Alliance News) -Â IXICO PLC on Monday said it will be collaborating with Microsoft Corp to develop its AI data analytics platform for the global pharmaceutical industry.
Shares in the data analytics firm were up 13% at 102.06 pence in London on Monday.
"Combining IXICO's portfolio of AI data analytics and scientific expertise in neurological diseases with Microsoft's cloud-based AI infrastructure, will provide a significant enabler for IXICO's delivery of clinical trial analytics solutions, at scale, to the pharmaceutical industry," IXICO said.
The two companies will work together to deliver IXICO's AI tools into global clinical trials for neurological diseases such as Alzheimer's disease and Huntington's disease.
"The partnership with Microsoft ensures we remain at the forefront of data analytics required by our global pharmaceutical clients, to provide new and valuable insights to reduce both the high cost of drug development and the time to market for urgently needed drugs across a wide range of neurological diseases," said IXICO Chief Executive Giulio Cerroni.
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.